Washington University Takes Position in Maze Therapeutics, Inc. $MAZE

Washington University bought a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 210,681 shares of the company’s stock, valued at approximately $5,463,000. Maze Therapeutics comprises about 3.1% of Washington University’s portfolio, making the stock its 2nd biggest holding. Washington University owned 0.48% of Maze Therapeutics at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of MAZE. Frazier Life Sciences Management L.P. increased its holdings in Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after purchasing an additional 438,274 shares during the period. CW Advisors LLC bought a new stake in shares of Maze Therapeutics in the 2nd quarter valued at about $371,000. Geode Capital Management LLC increased its stake in shares of Maze Therapeutics by 8.8% in the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after buying an additional 18,773 shares during the period. Ensign Peak Advisors Inc acquired a new position in shares of Maze Therapeutics in the second quarter worth approximately $227,000. Finally, Goldman Sachs Group Inc. bought a new stake in Maze Therapeutics in the first quarter valued at approximately $145,000.

Insider Buying and Selling at Maze Therapeutics

In related news, insider Atul Dandekar sold 72,400 shares of the company’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the completion of the sale, the insider owned 10,503 shares in the company, valued at approximately $426,001.68. This represents a 87.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CMO Harold Bernstein sold 45,000 shares of the stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 172,500 shares of company stock worth $7,002,267.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MAZE. BTIG Research boosted their price target on shares of Maze Therapeutics from $37.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Wedbush upped their target price on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, Raymond James Financial began coverage on Maze Therapeutics in a research note on Thursday, November 13th. They set an “outperform” rating and a $48.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $44.50.

Maze Therapeutics Price Performance

Shares of NASDAQ:MAZE traded down $1.00 during trading on Wednesday, reaching $44.34. 23,789 shares of the stock were exchanged, compared to its average volume of 353,091. The stock has a fifty day moving average of $40.36 and a two-hundred day moving average of $28.57. Maze Therapeutics, Inc. has a 1-year low of $6.71 and a 1-year high of $47.36. The firm has a market cap of $2.13 billion and a price-to-earnings ratio of -2.12.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.08.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.